Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109295 | 0.75 | GCGR (0.35) | SMN1; SMN2 | |
| SCHEMBL285375 | 0.74 | GCGR (0.40) | — | |
| SCHEMBL13059078 | 0.74 | NPSR1 (0.37) | SMN1; SMN2 | |
| SCHEMBL6050412 | 0.71 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL3384501 | 0.71 | P2RX7 (0.32) | — | |
| SCHEMBL285703 | 0.69 | MLYCD (0.40) | SMN1; SMN2 | |
| SCHEMBL96071 | 0.66 | — | — | |
| SCHEMBL2759501 | 0.66 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL22887889 | 0.63 | LMNA (0.30) | — | |
| SCHEMBL13439215 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427457-B1 | ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS | HOFFMANN LA ROCHE (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-8357703-B2 | Pyridines | HOFFMANN-LA ROCHE INC. (US) | 2013-01-22 | — | — | US | disclosed |
| EP-2427457-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20100286117-A1 | PYRIDINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| WO-2010127978-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286117-A1 | PYRIDINES | GABRA5, GABRA1, GABRA4 | SMN1; SMN2 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.